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Abstract
Background: Visceral Leishmaniasis (VL) is a vector-born disease that is caused by an
obligate intra-cellular protozoan parasite. Among parasitic diseases Leishmaniasis is
the second deadly parasitic disease next to malaria. Ethiopia is one of the six countries
in which more than 90% of global VL cases occur. Knowing the recent prevalence and
associated factors for Visceral Leishmaniasis-HIV co infection will help in the control of
the disease.
Objective: To assess Visceral Leishmaniasis - human immunodeficiency virus (HIV) co
infection and associated factors among adult Visceral Leishmaniasis patients admitted
at University of Gondar hospital, Gondar town, North West Ethiopia.
Methodology: A cross sectional retrospective review study was conducted on all (465)
patients with Visceral Leishmaniasis who had been admitted at University of Gondar
hospital from September 11, 2011 to June 30, 2013. Descriptive statistics like
Frequency tables, charts, mean with standard deviation and percentages were used to
present and summarize most of the variables.  Both bivariate and multivariate logistic
regression analysis were used to identify factors associated with Visceral Leishmaniasis
- HIV co infection.
Result: Out of the total study subjects 55 (11.8%) were Visceral Leishmaniasis -HIV co-
infected patients. Age 28-37 years [AOR= 9.56; 95% CI: 4.10-22.31], >37 years [AOR=
4.16; 95% CI: 1.32-13.06]) and type of residence (AOR=4.88, 95% CI 2.59-9.20) were
found to be significantly associated with VL-HIV co infection.
Conclusion and recommendation: Visceral Leishmaniasis-HIV co infection
prevalence was found to be lower than the other studies. Age and type of residence
were variables found to be significantly associated with Visceral Leishmaniasis-HIV co
infection. Ministry of health and other None Governmental organizations (NGOs) should
implement intervention strategies to reduce further the Visceral Leishmaniasis-HIV co
infection rate as a whole and particularly among the resident population of VL endemic
area.
11. Introduction
Visceral Leishmaniasis (VL), also called kala-azar, is a vector-born disease that is
caused by obligate intra-cellular protozoan parasites. They are members of the Leish
mania donovani complex (L. donovani and L. infant) and transmitted by female
phlebotomine sand flies (Old World) and Lutzomyia (New World). VL is endemic in semi
arid and arid areas and mainly affects the world's poorest populations (1).
Among parasitic diseases Leishmaniasis is the second deadly disease next to malaria
(2); and VL is the most severe form of Leishmaniasis that is almost always fatal if left
untreated. Over 90% of the estimated annual cases of 500,000 VL worldwide occur in
just six countries: Bangladesh, India, Nepal, Sudan, Ethiopia and Brazil. When we come
to our continent, Eastern Africa has the second highest number of VL cases, after the
Indian Subcontinent (3, 4).
Historically the first case of VL in Ethiopia was identified in 1942 in southern Ethiopia.
According to one study, annually an estimated 3700–7400 cases occur in Ethiopia (5).
VL now poses a significant public health problem in Ethiopia with expanding endemic
areas. When we see the Local Geographical distribution, VL is found in Tigray, Amhara,
Oromia, Afar, Somali and SNNPR (6). In the north, the responsible vector (the female
phlebotomine sand fly) is associated with Acacia-Balanites forest, and in the south with
termite hills (5, 7).
The north‐western VL focus in Ethiopia covers the semi‐arid Metema and Humera
plains in Amhara and Tigray regional states respectively. Historically, this area reported
only sporadic cases, but a marked increase occurred during the 1970s when migrants
from the non‐endemic highlands began to arrive in the area to harvest crops on the
large‐scale agricultural introduced at the time (8-13).
The development of HIV/AIDS pandemic during the last 25 years has modified the
spectrum of Leishmaniasis in clinical, diagnostic and epidemiological implication. From
2middle of 1980s, when the first case of Leishmaniasis associated with HIV was notifeid,
an increase in the case of co infection has been registered; to date cases in 35
countries have been detected (14). In East Africa more worryingly, particularly Sudan
and North West Ethiopia are facing a surge in Leishmaniasis/ HIV co-infection,
evidenced With reporting co-infection rate 34% (15).
HIV co-infection has become a major complication of Leishmaniasis and ignited calls for
the recognition of Leishmaniasis as AIDS defining illness. For both VL and HIV attack
the immune system of the body, they produce profound immune deficiency state. The
result and effect of this state is that VL accelerates the onset of full-blown AIDS and
shortens the life expectance of HIV-infected people (16, 17)
VL-HIV co-infection is characterized by a number of complexities including challenging
diagnosis and treatment. The standard serological tests are often less reliable in HIV
co-infection, atypical VL presentation is common. In terms of treatment, VL-HIV co-
infection is characterized by high mortality, increased drug toxicity and overall poor
treatment response. Moreover, even with initiation of antiretroviral treatment, multiple
VL relapses remain common. VL relapses tend to be associated with gradual loss in
treatment responsiveness. There are also concerns that VL-HIV co-infected individuals
could serve as a source and reservoir of drug resistant parasites
Although there have been studies showing VL-HIV co infection prevalence rate in North
West Ethiopia still it is very important to study the prevalence at this point in time.
Knowing the progress of VL-HIV co infection rate is very crucial in the control of VL as it
is becoming an emerging disease in the area.  (18)
32. Literature review
Several studies showed the incubation period of VL typically is to be 2-6 months but
may be shorter or much longer (19). Once the parasite gets an access in to the host’s
body then it migrates to the internal organs such as liver, spleen (that is why called
visceral) and bone marrow. VL If left untreated will almost always result in death of the
host. According to WHO, the clinical presentations of VL include prolonged high grade
fever (2 weeks or more), with remittent, intermittent or continuous characteristics,
splenomegaly, weight loss, anemia, cough, epistaxis, hepatomegaly and body
weakness. In rare occasions some patients will present with edema, jaundice, vomiting,
joint pain, abdominal pain, lymphadenopathy and diarrhea (20).
Even though the clinical presentation of VL is largely similar in the various endemic
areas there are also some differences between individuals and according to geographic
foci (21). For example lymph nodes are rarely found in Indian VL patients but are
frequent in Sudanese VL patients. The other example is hyper pigmentation which lead
to the name Kala-azar (black fever in Hindi), has been more described in VL patients
from the Indian subcontinent. (22).
Clinical features of cases of VL in HIV infected patients do not differ significantly from
those in immune competent patient. However the clinical presentation of VL in HIV
infected individuals can be atypical in severely immunocompromized patients (23).
In one study that patients with a CD4 count of <50 cells/mm2 had a lower frequency of
the clinical triad of fever, spleenomegally and hepatomegally. In the same study,
diarrhea or epigastragia was symptomatic in severely immunocopromized HIV infected
individuals as the result of the atypical location of the leishmania parasitization of the
digestive tract (24).From atypical features of VL, leishmanial involvement of the skin
was seen (8.2%)in HIV infected patients, but none of the HIV negative patients . As to a
result of one comparative study done in Spain, concerning diagnostic procedures of a
constant finding in HIV infected individuals with VL has low sensitivity (50% versus 80%;
of the serologic test of VL-HIV co infected and non HIVcoinfected VL patients
respectively (25).
4The spread of human immunodeficiency virus (HIV) infection to areas where visceral
Leishmaniasis (VL) is endemic has become a major challenge to the control of VL
infection (26). A good example is that, in 1995 the first reported seven cases of HIV and
Leishmania co infection in Ethiopia was found increased to 72 by 1998 (25). The other
example in Southern Europe, up to 70 per cent of VL cases with HIV infection had been
reported (27).
The epidemiological characteristics of VL- HIV co-infection can differ from one endemic
region to another due to parasite strain, vector behavior or socio-environmental condi-
tions of the exposed hosts in the VL-HIV co infection, factors that were associated
differently from population to population due to different reasons. According to the study
in Europe, it was known that people sharing needles were the main risk group to the
anthroponetic transmission of both infections. (28).
When we see one local study result, in humera, Tigray, the risk factors of VL-HIV co
infection considered were population mobility and socioeconomic problems. According
to the result of the study, 23% migrants and 40% of residents were HIV positive (29).
5Conceptual Framework
Figure 1: Conceptual frame of VL-HIV co infection and associated factors
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63. Significance of the study
VL is one of the neglected diseases that is spreading to previously non-endemic
areas. This study will assess the prevalence of VL-HIV co infection and the factors
that contribute to the spread of the disease. Knowing the recent prevalence and
contributing factors for VL-HIV co infection will help in the control of the disease.
Hopefully the study result will help the concerned bodies to intervene or to address
the problem accordingly and will be serving as a source of information to different
type of stake holders and partner’s serving to make possible interventions.
74. Objectives of the study:
4.1. General objective:
To assess VL-HIV co infection and associated factors among VL patients admitted at
University of Gondar Hospital.
4.2 Specific objective
1. To determine the prevalence of VL-HIV co infection among VL patients in
university of Gondar Hospital.
2. To identify factors associated with VL- HIV co-infection among VL patients in
university of Gondar Hospital.
85. Methodology:
5.1. Study design
A cross sectional retrospective review of clinical records was used to conduct
5.2. Study area and period:
The study area was UoGH. The hospital is a teaching and referral hospital located 738
Kms North West of Addis Ababa. UoGH is in close proximity to the main VL endemic
area in the country.  It has a Leishmaniasis research and treatment center that gives
diagnosis and treatment service to Leishmaniasis patients. This center was established
in 2005 and has 24 inpatient beds. The study was conducted from June 1st to July 31st,
2013.
5.3 Source population:
All VL patients who had been admitted from September 11, 2011 to June 30, 2013 in
the hospital were used.
5.4 Study subjects:
Adult VL patients (≥ 18 years old) who were diagnosed for VL by using parasitological
methods and serological positive result test from 2011-2013 were included.
5.5 Inclusion and exclusion criteria:
Inclusion criteria:
- VL patients diagnosed with demonstration of LD bodies from aspirates.
- VL patients diagnosed by clinical plus positive serological test.
Exclusion criteria:
- Patient charts with incomplete information of variables.
- Patients with unknown status of HIV.
- Patients with malaria co infection confirmed
95.6 Sample size:
All VL patients who were admitted at Gondar university hospital meeting the inclusion
criteria were included.
5.7 Sampling procedure:
All VL patients who had been admitted at Gondar University Hospital meeting the
inclusion criteria were included.
5.8 Study variables:
Dependent variables:
VL-HIV co infection
Independent variables:
Age, Sex,
Place of residence, Nutritional status
5.9 Data collection tools and procedures:
Data was collected by a health professional working in the Leishmaniasis research and
treatment center from patient chart. Patient’s charts were reviewed to collect data from
documented patients’ history, physical examinations and laboratory findings.
5.10 Data quality assurance procedures:
Data was collected by an experienced health professional working at the Leishmaniasis
research and treatment center of UoGH. The data collectors were properly informed
how to collect the data from the patients charts.
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5.11 Data management and analysis:
Data was coded and entered using SPSS for windows version 16. Missing values and
data clearance were checked. Frequency tables, percentages were used. Bivariate
analysis was conducted primarily to check which variables had association with the
dependent variable individually. Variables found to have association with the dependent
variables were then entered in to multivariate logistic regression for controlling the
possible effect of confounders and finally the variable which had significant association
were identified on the basis of OR, with 95%CI and 0.05 p-values.
5.12 Ethical considerations:
Ethical clearance was obtained from Institutional review board of University of Gondar,
Prior to enrolment supporting letter was obtained from UGH clinical director’s office. All
the data obtained from the patients chart was kept confidential at all times.
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6. Result:
6.1 Socio-demographic characteristics
Almost all of the study subjects (99.8 %) were males. The mean age was 25.19 + 6.43
years. A higher number of VL patients were in the age group between 18-27 years,
72.3%. Majority of VL patients were temporary residents (migrants) to endemic areas
79.4 (Table 1).
Table 1. Socio demographic characteristics of VL patients (n=465), UoGH,
Northwest Ethiopia, 2013
Variables frequency Percentage
(%)
Sex
Male 464 99.8
Female 1 0.2
Age
18-27 336 72.3
28-37 98 21.1
>=38 31 6.7
Residency
Permanent  Resident 96 20.6
Migrant (Temporary  resident) 369 79.4
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6.2 Clinical manifestations and laboratory findings of VL patients
Fever was found to be the most commonly reported symptom (97%) followed by weight
loss (94.2%), loss of appetite (92.9%), body weakness (72%), and cough (58.6%).
Majority of the patients, (93.5%) have history of travel to VL endemic areas and patients
with fever more than 2 weeks were to account (96.3%) and less than 2 weeks 3 (0.6%)
(Table 2).
The most frequent objective findings were spleenomegally (96.3%), pal mar pallor
(75.3%) and pedal edema (32.3%).Concerning the nutritional status of VL patients,
(87.9%) had malnutrition. From these, mild to moderate malnutrition was found in
(48.1%) and (39.8%) were severely malnourished.  As to the laboratory result, we see
leucopenia (98.5%), anemia (92.5%), and thrombocytopenia (91.2%), elevated SGOT
(82.4%), elevated SGPT (42.2%), increased creatinine (15.3%) and increased BUN
(11%) (Table 2).
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Table 2. Common clinical manifestations and laboratory   findings of VL patients,
UoGH, Northwest Ethiopia, 2013
No. and % of patients with
VL
All N= 465
(%)
HIV positive
(n=55)
HIV
negative
(n= 410)
Fever Yes 42 409 451 (97)
14 (3)No 13 1
Duration of fever >2weekss
<2weeks
42
0
406
3
448 (96)
3 (0.6)
Weight loss yes
no
53
2
385
25
438(94.2)
27 (5.8)
Loss of appetite yes
no
52
3
380
30
432 (92.2)
33 (7.1)
Body weakness yes
no
43
12
292
118
335 (72)
130 (28)
Cough yes
no
30
25
238
172
268 (57.6)
197 (42.2)
Epitasis yes
no
14
41
154
256
168 (36.1)
279 (63.9)
Dragging sensation yes
no
11
44
81
329
92 (19.8)
373 (80.2)
Diarrhea yes
no
19
36
46
364
65(14)
400(86)
Nausea and
vomiting
yes
no
6
49
47
363
53 (11.4)
412 (88.6)
Palmer
pallor(pale
conjunctiva)
yes
no
35
20
315
95
350 (75.3)
115(24.7)
Pedal edema yes
no
13
44
139
271
150 (32.3)
315 (67.7)
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Jaundice yes
no
8
47
59
351
67 (14.4)
398 (85.6)
Spleenomegally yes
no
51
4
397
13
448 (96.3)
17 (3.7)
Hepatomegally yes
no
14
41
57
353
71 (15.3)
394 (84.7)
Lymphadenopathy yes
no
3
52
21
389
24 (5.2)
441 (94.8)
Skin color change yes
no
1
54
3
470
4 (0.9)
461 (99.1)
BMI Severe
malnutrition
<16kg/m2
19 166 185 (39.8)
Mild to
moderate
malnutrition
16-18.49
kg/m2
30 194 224 (48.2)
Normal
(≥18.5
kg/m2)
6 50 56 (12)
Leucopenia yes
no
53
2
405
5
458 (98.5)
7 (1.5)
Anemia yes
no
52
3
378
32
430 (92.5)
35 (7.5)
Thrombocytopenia yes
no
43
12
381
29
424 (91.2)
41 (8.8)
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Elevated SGOT Elevated
Not elevated
44
11
225
185
269 (57.9)
196 (42.1)
Elevated SGPT Elevated
Not elevated
19
36
63
347
82 (17.6)
383 (82.4)
BUN Increased
Normal
6
49
45
365
51(11)
414 (89)
Creatinine Increased
Normal
9
46
62
348
71(15.3)
394 (84.7)
7.3 Laboratory diagnosis for VL
The most commonly used method of VL diagnosis was parasitological (92.9%)
and the other method used was serologic test (7.1%). Parasitological confirmation
was carried out for (92%) HIV negative and (100%) HIV positive patients. Sites
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that were used for aspiration were spleen, bone marrow and lymph node that
each account for (62.6%), (29.2%) and (1.1%) respectively.  Spleenic aspiration
was the commonest procedure employed in (61.7%)  HIV negative and (69.1%) in
HIV positive patients followed by bone marrow puncture (29.3%) for HIV negative
and (29.1%) HIV positive patients. Lymph node aspiration was done in (1%)  HIV
negative and (1.8%)  HIV positive patients.
7.4 Prevalence of VL- HIV co infection
Among the total 465 study subjects the prevalence of VL-HIV co infection was
found to be 11.8% (figure 3).
Looking at different age categories, prevalence of VL-HIV co infection patients in
the age category between 18-27 years had 5.7%, 28-37 years had 26.5% and
>37 had 32.3%. The prevalence of VL-HIV co infection among residents and
migrants was found to be 29.2% and 7.3% respectively (Table 2).
Figure 2: Prevalence of VL- HIV co infection, UoGH, Northwest Ethiopia,
2014
11.80%
88.20%
Prevalence of VL-HIV co-infection
HIV positive
HIV negative
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7.5 Factors associated with VL-HIV co-infection
The association between selected socio-demographic variables on VL-HIV confection of
the Study participants was investigated using both bivariate and multivariate logistic
regression techniques. Variables with significant association considered in the bivariate
and multivariate logistic regression analysis were age and residence. Accordingly, VL
patients in the age group between 28-37 years were 6 times more likely to have VL-HIV
co infection[AOR= 6.16; 95% CI: 3.14-12.01]and the age group >37 years were found to
be about 6 times more likely to be VL-HIV co infected [AOR= 5.98; 95% CI: 2.35-5.25].
Permanent residents were about 5 times more likely to acquire VL-HIV co infection
when compared to temporary residents (migrants) [AOR=4.88, 95% CI 2.59-9.20]
(Table 3).
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Table 3. Factors in VL-HIV co infection, UoGH, Northwest Ethiopia, 2013
HIV status
All N=
465 (%)
COR (95% CI) AOR (95% CI)
HIV
positive
(n=55)
HIV
negative
(n=410)
Age
18-27 19 (34.6) 317 (77.3) 336(72.3) 1
28-37 26 (47.3) 72 (17.6) 98(21.1) 6.02(3.16-
11.48)**
6.16 (3.14-
12.07)**
>37 10 (18.2) 21 (5.1) 31(6.7) 7.94(3.28-
19.23)*
5.98 (2.35-5.25)**
Residency
Resident 28 (50.9) 68 (16.6) 96(20.6) 5.21(2.89-
9.40)**
4.88 (2.59-9.20)**
Migrant 27(49.1) 342 (83.4) 369(79.4) 1
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7. Discussion:
In this study almost all VL patients (99.8%) were males and the result is similar to
previous report (96.3%) in the same study area (23). A higher proportion of VL patients
were temporary residents (migrants) 79.4 % and the possible reason for this could be a
higher number of non immune (previously unexposed) daily laborers population
migrations to the endemic areas (29).
VL patients in the age group between 28-37 years and >37 years were found  more
likely to be VL-HIV co infected when compared to the age group between 18-27 years.
A similar result was reported by a study conducted in the same area that had reported
mean age of HIV-positive patients was significantly higher than for HIV-negative
patients  32.2(7) vs 23.5(5.7), OR= 0.78, 95% CI 0.75–0.85, P < 0.001) (30).
In this study significant association was found with residence and VL- HIV co-infection.
A higher proportion of HIV positives 28 (50.9%) were residents compared to 68 (16.6%)
HIV negative patients (AOR= 4.88, 95% CI 2.59-9.20). This could be due to the fact that
HIV infected residents have lifelong exposure time and risk to be infected and develop
the disease than migrants. This is supported by a result from a study which showed a
higher risk for migrants who had spent a year or more in an endemic area compared to
those with shorter duration of exposure. A report in 2008, KAH (Humara, North west
Ethiopia) treated a total of 376 VL patients of whom 23% of migrants and 40% of
residents were HIV positive (MSF-H, unpublished data) (28). `
According to the finding of this study the prevalence of VL-HIV co infection is 11.8%.
This is lower than a study conducted in the same study area that reported 38.2% VL-
HIV co infection prevalence (30). This difference could be explained by decreasing
prevalence of HIV in the country in general. The HIV/AIDS Prevention and Control
Office (FHAPCO) reported that adult HIV prevalence level has fallen from 2.1% in 2011
to 1.3% in 2013. According to FHAPCO report, expanded HAART service in the health
care facilities could have improved immune status of HIV patients that helps the
individuals not to develop the disease. The HAART service expansion also explained
that in 2001 there were only three ART centers but the number has increased to 838 in
2013 (31).The effect of HAART other than Ethiopia showed that the number of co
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infected individuals in European countries where the disease is endemic, fell sharply
(32, 33 and 34).Another study result showed when  Comparing to those who received
no antiretroviral therapy, Patients treated with highly active antiretroviral therapy
(HAART) had a 59% reduction of risk for developing the disease (32).
8. Limitation of the study:
This study was conducted on secondary data because of this important
information of some variables were not found.
9. Conclusion:
The overall HIV-VL co-infection rate was found to be lower when compared to
previous studies done in the same study area. Age and residency were found to
be significantly associated factors that contribute for VL-HIV co-infection. Age
group between 28-37 years and >38 years were found to be at higher risk for VL-
HIV co infection. A higher VL-HIV co infection prevalence rate was found among
endemic area permanent residents than temporary residents (migrants).
10. Recommendation
Ministry of health should implement intervention strategies to avert the high VL-
HIV co infection rate among endemic area residents. These can include early
identification of HIV cases and giving health education about VL-HIV co infection
to create awareness. In addition expansion of HAART service in the health care
system of endemic areas is important. Otherwise further research needs to be
carried out to identify the reason why VL-HIV co infection rate is high among
endemic residents than migrants.
Ministry of health should also give attention to the age 28 years and above to
reduce their risk for VL-HIV co infection.
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Annex i: Data collection instrument
Demographic characteristics:
1. Age in years: _________
2. . Sex: 1. Male 2. Female
3. Place of residence: To which of the following categories the subject belongs to
the kalazar endemic areas?
1. Permanent 2. Migrant
I. Subjective findings:
1. History of fever? 1. Yes 2. No
2. History of fever for how long? 1. < 2 wks 2. > 2 wks
3. Rigors and chills associated with fever? 1. Yes 2. No
4. History of sweating? 1. Yes 2. No
5. History of body weakness? 1. Yes 2. No
6. History of chills and rigors? 1. Yes 2. No
7. History of vertigo? 1. Yes 2. No
8. History of Tinnitus? 1. Yes 2. No
9. History of blurring of vision? 1. Yes 2. No
10.History of headache? 1. Yes 2. No
11.History of loss of appetite? 1. Yes 2. No
12.History of weight loss? 1. Yes 2. No
13.History of body weakness? 1. Yes 2. No
14.History of nausea and vomiting? 1. Yes 2. No
15.History of diarrhea? 1. Yes 2. No
16.History of cough? 1. Yes 2. No
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17.History of epitasis? 1. Yes 2. No
18.History of travel to kala-azar endemic area? 1. Yes 2. No
19.History of drugging sensation on the LUQ area? 1. Yes 2. No
II. Objective findings:
1. Weight (KG):_______ Height (cm):_______BMI:_____________
2. Body temperature (In Celsius):_________
3. Palpable spleen 1. Yes 2. No
4. Hepatomegally 1. Yes 2. No
5. Jaundice of the sclera 1. Yes 2. No
6. Pain less palpable lymph nodes 1. Yes 2. No
7. Palmar pallor/ pale conjunctiva 1. Yes 2. No
8. Pethichial rush 1. Yes 2. No
9. Skin change- gray/dark 1. Yes 2. No
10.Pedal edema 1. Yes 2. No
11.Site of aspiration? 1. Spleenic 2. Bone marrow 3. Lymph node
12.Diagnosis? 1. Parasitic 2. Serologic
13.Other objective findings:
___________________________________________________
III. Laboratory findings:
1. Serological test (rK39) 1. Pos 2. Neg
2. LD body isolation: 1. Yes 2. No
3. Hemoglobin (gm/dl):________
4. Platelet count: _____________
5. Total WBC: ________________
6. Neutrophils: _______________
7. Lymphocytes: ______________
8. Liver enzyme: SGOT_________ SGPT_________
9. Renal function test      BUN____________             Creatinine________
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10.HIV status: 1. Negative 2. Positive 3. Missing/not done
11. Cd4 count: ____________
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